To include your compound in the COVID-19 Resource Center, submit it here.

Pain reports Phase I data for AD candidate PTI-125

In October, Pain Therapeutics Inc. (NASDAQ:PTIE) reported data from a

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE